SCHEMBL7558686

SCHEMBL7558686

COC(=O)c1ccc2ccccc2c1C(=O)c1ccc2cc(OC)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ABCG2 Q9UNQ0 4/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
MTNR1A P48039 1/20 0.47
KMT2A Q03164 3/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PLA2G2A P14555 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2A6 P11509 1/20 0.45
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
MMP3 P08254 1/20 0.44
GCGR P47871 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560679 0.88 KDM4E (0.57) KDM4EALDH1A1LMNASMN1; SMN2ABCG2
SCHEMBL7558683 0.87 KDM4E (0.51) KDM4EALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL8440232 0.84 LCK (0.52) KDM4EALDH1A1LMNANPC1RAB9A
SCHEMBL7558808 0.82 KDM4E (0.55) KDM4EALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL9002749 0.80 LCK (0.48) KDM4EALDH1A1LMNAKMT2AHPGD
SCHEMBL29404644 0.79 NCEH1 (0.59) KDM4EALDH1A1LMNAKMT2AHPGD
SCHEMBL71131 0.79 NCEH1 (0.59) KDM4EALDH1A1LMNAKMT2AHPGD
SCHEMBL8442119 0.77 LCK (0.54) KDM4EALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL7560673 0.77 KDM4E (0.60) KDM4EALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL7558032 0.76 CDC25B (0.55) KDM4EALDH1A1LMNAKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052354-A1 Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction SCHERING AG 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052354-A1 Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction TNNI3, NPR1, LPXN KDM4E 2293/4885ALDH1A1 3405/4885LMNA 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.